Who’s better? BIO International vs J.P. Morgan Healthcare
Hello to the 15K of you that are at the BIO International Convention in San Francisco!
Biotechnology companies, academic institutions and state biotech organizations flock to this international event to network with each other, learn about each other’s pipelines and capabilities, and to get deals done. This meeting covers a broad spectrum of life science domains including drug discovery, biomanufacturing, genomics, animal health, biofuels, nanotechnology and cell therapy.
Even with all of this content and opportunities to connect, there’s debate about it being the “place to be”. Damien Garde at STAT posed this question and pointed out that the J.P. Morgan Healthcare Conference is THE meeting where multi-billion dollar deals are made and mergers announced.
Garde has some good points. However, we’d hedge that the deals that close at J.P. Morgan are initiated at BIO. STAT also gives BIO the edge for startups seeking funding as compared to the ‘by invitation only’ J.P. Morgan meeting. And, if you do want to mix your deal-making with learning objectives, Lodescores show that BIO bests J.P. Morgan for Educational experience.